Kiniksa Pharmaceuticals Ltd.

As of July 29, 2025, Kiniksa Pharmaceuticals Ltd. is considered an attractive investment due to its undervaluation despite a high P/E ratio of 294.42, strong year-to-date returns of 81.60%, and favorable comparisons to peers like Amneal Pharmaceuticals and NewAmsterdam Pharma.

As of July 23, 2024, Kiniksa Pharmaceuticals Ltd. is considered overvalued with a risky valuation grade, reflected by a price to book value of 2.78, an EV to sales ratio of 2.09, and negative profitability metrics, despite a year-to-date stock performance of 45.20% that outpaces the S&P 500's 2.44%.

As of May 28, 2025, the technical trend is bullish, supported by strong indicators like the MACD and Bollinger Bands, despite some mixed signals from the KST and Dow Theory.

As of March 2022, the management team of Kiniksa Pharmaceuticals Ltd. includes Mr. Sanjiv Patel (Chairman and CEO), Dr. Felix Baker (Lead Independent Director), and Directors Mr. G. Bradley Cole, Dr. Stephen Biggar, Dr. Richard Levy, and Mr. Thomas Malley.

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutic medicines for debilitating diseases. As of March 2025, it reported net sales of $138 million and a market cap of approximately $1.17 billion.

As of Jun 18, Kiniksa Pharmaceuticals Ltd. has a market capitalization of 1,174.17 million and reported net sales of 481.16 million with a net loss of 16.95 million over the latest four quarters.